South Korea
· Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 100.59 billion. The enterprise value is 120.14 billion.
| Market Cap | 100.59B |
| Enterprise Value | 120.14B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | Mar 13, 2025 |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 12.78% |
| Owned by Institutions (%) | 8.39% |
| Float | 12.69M |
Valuation Ratios
The trailing PE ratio is 23.34.
| PE Ratio | 23.34 |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | 552.60 |
| P/OCF Ratio | 30.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.67, with an EV/FCF ratio of 659.98.
| EV / Earnings | 27.87 |
| EV / Sales | 0.75 |
| EV / EBITDA | 13.67 |
| EV / EBIT | 21.42 |
| EV / FCF | 659.98 |
Financial Position
The company has a current ratio of 2.44, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.44 |
| Quick Ratio | 1.41 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 3.35 |
| Debt / FCF | 161.88 |
| Interest Coverage | 5.12 |
Financial Efficiency
Return on equity (ROE) is 4.81% and return on invested capital (ROIC) is 2.93%.
| Return on Equity (ROE) | 4.81% |
| Return on Assets (ROA) | 2.13% |
| Return on Invested Capital (ROIC) | 2.93% |
| Return on Capital Employed (ROCE) | 3.97% |
| Revenue Per Employee | 657.51M |
| Profits Per Employee | 17.66M |
| Employee Count | 244 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 3.57 |
Taxes
In the past 12 months, Kukje Pharma has paid 1.07 billion in taxes.
| Income Tax | 1.07B |
| Effective Tax Rate | 19.94% |
Stock Price Statistics
The stock price has increased by +1.69% in the last 52 weeks. The beta is 0.87, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +1.69% |
| 50-Day Moving Average | 4,683.00 |
| 200-Day Moving Average | 5,159.53 |
| Relative Strength Index (RSI) | 60.16 |
| Average Volume (20 Days) | 281,182 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 160.43 billion and earned 4.31 billion in profits. Earnings per share was 211.65.
| Revenue | 160.43B |
| Gross Profit | 84.80B |
| Operating Income | 5.61B |
| Pretax Income | 5.38B |
| Net Income | 4.31B |
| EBITDA | 8.79B |
| EBIT | 5.61B |
| Earnings Per Share (EPS) | 211.65 |
Balance Sheet
The company has 9.93 billion in cash and 29.47 billion in debt, giving a net cash position of -19.53 billion or -959.34 per share.
| Cash & Cash Equivalents | 9.93B |
| Total Debt | 29.47B |
| Net Cash | -19.53B |
| Net Cash Per Share | -959.34 |
| Equity (Book Value) | 90.77B |
| Book Value Per Share | 4,457.28 |
| Working Capital | 33.24B |
Cash Flow
In the last 12 months, operating cash flow was 3.31 billion and capital expenditures -3.12 billion, giving a free cash flow of 182.03 million.
| Operating Cash Flow | 3.31B |
| Capital Expenditures | -3.12B |
| Free Cash Flow | 182.03M |
| FCF Per Share | 8.94 |
Margins
Gross margin is 52.86%, with operating and profit margins of 3.50% and 2.69%.
| Gross Margin | 52.86% |
| Operating Margin | 3.50% |
| Pretax Margin | 3.36% |
| Profit Margin | 2.69% |
| EBITDA Margin | 5.48% |
| EBIT Margin | 3.50% |
| FCF Margin | 0.11% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.62%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.62% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | n/a |
| Buyback Yield | -0.28% |
| Shareholder Yield | 0.34% |
| Earnings Yield | 4.28% |
| FCF Yield | 0.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 2.28 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.28 |
| Piotroski F-Score | 6 |